申请人:Incyte Corporation
公开号:EP2264030A1
公开(公告)日:2010-12-22
The present invention provides compounds of the formula I:
its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.
本发明提供了式 I 的化合物:
其对映体、非对映体、外消旋混合物、原药、结晶形式、非结晶形式、无定形形式、其溶解物、其代谢物和药学上可接受的盐,其中环 A 取代基团在以下公开内容中完全定义。式 I 的化合物是基质金属蛋白酶和脱落酶等金属蛋白酶的抑制剂,可用于治疗类风湿性关节炎、银屑病、肿瘤性疾病、过敏症等疾病以及所有需要抑制 MMPs 的疾病。